Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.

ABSTRACT: BACKGROUND:Neoadjuvant radiotherapy has been shown to improve marginal negative resection and local control of Pancreatic Ductal Adenocarcinoma (PDAC). However, whether it improves overall survival (OS) in patients with non-metastatic PDAC remains controversial. Therefore, the purpose of this study was to analyze the benefits of only surgery, neoadjuvant radiotherapy, adjuvant radiotherapy, and surgery plus chemotherapy for OS in patients with non-metastatic PDAC. METHODS:PDAC diagnosed by surgical histopathology in the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2016 was selected. Kaplan-Meier analysis was used to compare the prognosis of patients with different treatments. Cox proportional risk model was used to analyze independent predictors of OS. Propensity score matching (PSM) was used to analyze the tumor prognosis of different treatment methods. RESULTS:Before PSM analysis, the OS of surgery plus chemotherapy (HRs?=?0.896, 95%CIs, 0.827-0.970; P?=?0.007) were significantly better than the other three treatments for stage T1-3N0M0 PDAC patients. For stage T1-3N?+?M0 patients, adjuvant radiotherapy (HRs?=?0.613, 95% CIs, 0.579-0.649; P?

SUBMITTER: Wang D 

PROVIDER: S-EPMC7222314 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature